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Abstract
Significance: It is generally accepted that reactive oxygen species (ROS) scavenging molecules or antioxidants exert
health-promoting effects and thus their consumption as food additives and nutraceuticals has been greatly encouraged.
Antioxidantsmay be beneficial in situations of subclinical deficiency and increased demand or acutely upon high-dose
infusion. However, to date, there is little clinical evidence for the long-term benefit of most antioxidants. Alarmingly,
recent evidence points even to health risks, in particular for supplements of lipophilic antioxidants.Recent Advances:
The biological impact of ROS depends not only on their quantities but also on their chemical nature, (sub)cellular and
tissue location, and the rates of their formation and degradation. Moreover, ROS serve important physiological
functions; thus, inappropriate removal of ROSmay cause paradoxical reductive stress and thereby induce or promote
disease. Critical Issues: Any recommendation on antioxidants must be based on solid clinical evidence and patient-
relevant outcomes rather than surrogate parameters. Future Directions: Such evidence-based use may include site-
directed application, time-limited high dosing, (functional) pharmacological repair of oxidized biomolecules, and
triggers of endogenous antioxidant response systems. Ideally, these approaches need guidance by patient stratification
through predictive biomarkers and possibly imaging modalities. Antioxid. Redox Signal. 23, 1130–1143.
Introduction
S ince the 1970s, oxidative stress has been evoked as acontributor to pathogenesis and thousands of studies
have reported protective or therapeutic benefits of antiox-
idants in cellular and animal models of cardiovascular
(43), neurodegenerative (62), and inflammatory diseases
(75) and cancer (110) diseases. As a result, antioxidant
supplements have been promoted as nutraceuticals and
antioxidant vitamins, often with little or no clinical control
or evidence.
Failures and risks of antioxidants
However, with the exception of a few studies (50, 53, 67),
antioxidants have almost always failed to show a significant
effect in long-term clinical trials performed according to the
criteria of evidence-based medicine (132). For example, the
spin-trapping synthetic antioxidant NXY-059, developed for
acute treatment of ischemia injury due to stroke, represents
one of the most prominent and costly failures of a synthetic
antioxidant ever clinically developed (135). Another exam-
ple is the recent failure of the 2CARE study on the use of
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coenzyme Q10 in the largest ever therapeutic trial for Hun-
tington’s disease (61b).
In some recent meta-analyses, a beneficial effect of anti-
oxidants was claimed, such as for vitamin C in breast cancer
(47), atrial fibrillation (2), stroke (25), or endothelial function
(5). However, a more definitive proof of antioxidant benefit
would have been required to measure plasma levels of the
administered compounds. The latter was also a major limi-
tation in several large clinical trials, for example, the Heart
Outcomes Prevention Evaluation (HOPE) (137, 158) and the
HOPE-The Ongoing Outcomes (17). Even worse than no
effect, chronic use of multivitamins without clinical control,
especially lipid-soluble antioxidants at dosages above the
upper safety limit, may be associated with increased health
risks (Table 1) (13).
In sedentary rats, vitamin E administration reduced liver
oxidative damage, while in rats submitted to chronic exercise,
vitamin E decreased antioxidant levels (148). It remains con-
troversial whether chronic intake of high concentrations of
certain antioxidants has a harmful effect on performance and
whether this might be due to redox cycling reactions that could
even convert an antioxidant into a pro-oxidant (18, 116, 125).
Taken together, these observations indicate that to identify
efficient redox-based therapeutic strategies, there is first a need
to reevaluate the physiological and pathological relevance of
reactive oxygen species (ROS), and then to determine whether
an antioxidant approach is feasible and in which situations.
Another example of the failure of antioxidant therapy is
provided in pre-eclampsia. Some studies have reported a
modest increase in oxidative stress biomarker, F2-
isoprostane, at late stages of pregnancy (112) as well as low
levels of gamma-tocopherol may be considered as a
risk factor for pre-eclampsia (63). However, concomitant
supplementation with vitamin C and vitamin E did not pre-
vent pre-eclampsia in women at risk and, even worse, this
treatment increased the rate of births with low weight (121).
Absorption, distribution, metabolism, and excretion of
specific antioxidants are essential aspects of antioxidant
therapy that have not been analyzed in detail for many
compounds, especially for nutraceuticals. Yet, the pharma-
cokinetic (bioavailability and frequency of administration)
and pharmacodynamic (therapeutic index and onset of ac-
tion) properties of specific antioxidants are critical to assess
their clinical usefulness (11). This is best exemplified with
compounds that need to cross the blood–brain barrier (73).
Redefining oxidative stress
The term, ROS, groups a number of oxygen-containing
molecules with different chemical reactivity. ROS include
not only O2
-, hydroxyl radicals, alkoxyl and peroxyl radi-
cals, NO, and nitrogen dioxide radicals but also nonradical
species such as hydrogen peroxide (H2O2), hypochlorite,
peroxynitrite, singlet oxygen, lipid peroxides, and others. At
the enzymatic level, the discovery of superoxide dismutases
(SOD), catalase, peroxiredoxins, sulfiredoxins, and glutathi-
one peroxidases implied that the formation of at least some
forms of ROS, for example, O2
-, can be harmful if not
properly controlled (24, 90, 140).
At the chemical level, when talking about ROS and ROS
scavengers, it is crucial to know what kinds of molecules are
involved. For instance, in the case of ascorbate, this antiox-
idant avidly reacts with alkyl, peroxyl, and alpha-
tocopheroxyl radicals, modestly with superoxide, and poorly
with H2O2. While ascorbate also reacts very rapidly with
hydroxyl radicals, this unlikely contributes to its antioxidant
Table 1. Meta-Analyses and Reviews of Chronic Oral Vitamin and Antioxidant Substitution
Study type Antioxidants assessed Objectives and endpoint Conclusions
Meta-analysis
(150)
b-Carotene and vitamin E Effects on CVD-related and
unrelated mortality
and morbidity
b-Carotene possibly harmful;
vitamin E no effect
Meta-analysis
(14)
b-Carotene, vitamins
A, C, E, and selenium,
alone and mixed
Incidence of cancer
and dose–response
effect on mortality
High-dose vitamin E may increase
mortality; selenium may be
beneficial in the prevention of
cancer; other antioxidants no effect
Review (81) b-Carotene, vitamin E,
and antioxidant cocktail
Primary and secondary prevention
of CVD and progression
of intima-to-media thickening
Data do not justify supplementing
antioxidants beyond the current
dietary guidelines
Meta-analysis
(102)
Vitamin E alone
and in combination
Dose–response effect
on all-cause mortality rates
High-dose vitamin E may increase
all-cause mortality and should
be avoided.
Meta-analysis
(133)
Vitamin E All relevant CVD-related
endpoints and lipid levels
Vitamin E does not affect
CVD-related outcomes.
Meta-analysis
(36)
Vitamin E alone
and in combination
Odds ratio of relevant
CVD-related endpoints
Vitamin E no effect
Meta-analysis
(13)
b-Carotene, vitamins
A, C, E, and selenium,
alone and in combination
All-cause mortality with regard
to other factors such as dose
and type of supplement
b-Carotene and vitamins A and E
may increase mortality
Decision tree
and Markov
chain model
(33)
Vitamin E alone
and in combination
Event rates and quality-
adjusted life year
Nonselective application
of high-dose vitamin E
does more harm than good
CVD, cardiovascular disease.
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activity because hydroxyl radicals are so reactive that they
react with essentially all molecules at diffusion-controlled
rates so that ascorbate will always be outcompeted.
Originally, the term oxidative stress was primarily defined
by quantitative deviation from a supposedly neutral steady-
state level of ROS (136, 140). Quantitative deviation means a
state where either increased formation of ROS or diminished
cellular antioxidant defense leads to disequilibrium and a
shift in the cellular redox balance (Fig. 1). However, we now
know that for ROS, as for many other messengers, cellular
levels are less relevant compared with subcellular concen-
trations (20, 68).
Quantity, that is, deviation from an overall equilibrium, on its
own cannot explain or define oxidative stress. In fact, at least in
many experimental models, only very moderate overall in-
creases in ROS levels are observed, yet correlating with ap-
preciable dysfunction and accumulation of relevant biomarkers
(154). Therefore, in addition to quantitative accumulation of
ROS, the oxidative stress concept needs to integrate other fea-
tures of ROS such as their subcellular or tissue location, che-
mical nature (e.g., O2
-, H2O2, ONOO
-), kinetics of formation
and degradation, and time of exposure (Fig. 2) (76). Examples
include the expression of NOX1 in hypertension, causing only a
small increase in ROS (154), but via its caveolar localization, its
product O2
- interferes with NO formation and its vasodilator
function (88); conversely, H2O2 induces endothelial nitric oxide
synthase (eNOS) and is a vasodilator (34, 100).
Physiological functions of ROS
Another potential problem of antioxidants is the many
physiological functions of ROS. The discovery of NOX
isozymes, the only known enzyme family with the sole pur-
pose of producing ROS, indicated that at least certain ROS
are physiologically essential. For a long time, and still for
newcomers to the field, it was considered that the increased
formation of ROS equates to oxidative stress and represents a
biochemical accident that can be prevented by systemic an-
tioxidant treatment (mostly cell culture or animal-based
studies using high doses of the drug). This misconception is
based on the wrong assumption that ROS fulfill no physio-
logical function. The first description was the role of NOX2
(then termed gp91phox) in immunocyte oxidative burst.
Other NOX isoforms have different physiological roles in
nonphagocytic cells, for example, in hearing (111), thyroid
hormone synthesis (32) and angiogenesis, and the constric-
tion of the ductus arteriosus (72). Furthermore, ROS play
important roles in normal cellular function, including dif-
ferentiation, proliferation, aging, and repair processes (124).
Nitric oxide/nitrogen monoxide (NO) and H2O2 seem to act
primarily as messenger molecules, for example, they essen-
tially contribute to vasodilation, proliferation (103), and pro-
mote or counteract programmed and spontaneous cell death
(apoptosis and necrosis) (12, 147).
In working muscles, ROS are generated in the microcircu-
lation, sarcolemma, and mitochondria (64) as part of a ben-
eficial physiological response. Depending on mode, intensity,
and duration of the exercise, antioxidants thus affect exer-
cise capacity and adaptation processes (Fig. 3). For example,
antioxidants, such as vitamins C and E, appear to blunt exercise-
induced mitochondrial biogenesis (116); even anaerobic exer-
cise, for example, strength training, can be affected with respect
to muscle strength and hypertrophy (94, 117). Other observa-
tions indicate that vitamin C supplementation decreases oxi-
dative stress and might increase exercise performance only in
those subjects with low initial concentration of vitamin C (114).
Both the redefinition of oxidative stress (from a global
redox disequilibrium to very subtle, even subcellular chan-
ges) and the many physiological functions of the same ROS
that also cause disease may explain why systemic and
chronically applied antioxidants may not necessarily have
beneficial effects or even cause reductive stress or harm (9).
ROS
Exogenous
Antioxidants
Neutral or
beneficial
Detrimental
FIG. 1. Classical view on oxidative stress and antioxi-
dants. Initially reactive oxygen species (ROS) were seen as a
metabolic by-product that in low concentrations is neutral or
beneficial (having signaling effects), but in higher concentra-
tions can lead to a cellular, tissue, or even whole body redox
imbalance with detrimental consequences. Hence, it was seen
feasible to initiate systemic treatment with ROS scavengers as
antioxidants to reverse this imbalance by reducing ROS levels.
Such exogenous antioxidants were not expected to have any
possible side effects. To see this illustration in color, the reader
is referred to the web version of this article at www.liebertpub
.com/ars
ROS
Enzyme
Source A
Detrimental
Enzyme
Source B Inhibitor drug
Beneficial
Signalling
(endogenous)
Antioxidant
Enzymes
Functional
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Quantity
Cell-type
Sub-cellular
ROS type
FIG. 2. Refined scheme and major changes in our
understanding of oxidative stress and possible interven-
tions. ROS are now viewed not necessarily as disease-
triggering molecules but also as essential signaling messengers.
The distinction between beneficial and detrimental effects of
ROS cannot be defined by overall cell, tissue, or whole body
quantity of ROS formation. Instead, these differences may be
due to different sources of ROS in different cellular and sub-
cellular compartments (physiological and nonphysiological),
the type of ROS being formed (e.g., superoxide vs. hydrogen
peroxide). In light of the many negative results with broad
systemic antioxidants, new therapeutic approaches may in-
clude more targeted or specific antioxidants, limiting antioxi-
dants only to situations with acute and extremely high ROS
levels, or indirect antioxidant mechanisms by upregulating
endogenous antioxidant defense systems. To see this illustra-
tion in color, the reader is referred to the web version of this
article at www.liebertpub.com/ars
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For example, ROS formed during the oxidative burst of
phagocytic cells protect against infection and tumor cells,
which imposes the risk of any chronically applied antioxidant
(71, 118, 129). On the other hand, experimental data support
the hypothesis that vitamin C affects epigenetic reprogram-
ming toward less invasiveness of tumor cells (44, 149, 156).
Paradoxes between in vitro versus in vivo and animal
versus human studies
One potentially large problem in the field of ROS may be
the use of in vitro models to observe cytoprotective effects of
antioxidants. Standard cell culture, isolated organs, and cell-
free models represent artifact-prone conditions due to a very
high partial oxygen pressure of about 0.2mM (79). In addition,
the frequently published exposure of cells to a bolus of high
micromolar concentrations of an oxidant is nonphysiological,
even if this may be reached in some subcellular compartments
or intercellular spaces. It likely impairs cellular antioxidant
defenses in a manner that is hardly ever seen in vivo (46).
Yet, it remains puzzling why so many in vivo animal studies
that have shown beneficial effects of antioxidants were later not
translatable into the clinic because they failed to show benefit or
in some studies, HOPE (95, 157), HOPE-TOO (89), a pro-
spective study with vitamin C in postmenopausal women with
diabetesmellitus (82), and a prospective cohort study conducted
among 83,639 healthy male US physicians (107), worsened
outcome (Table 1). However, these and other studies often do
not monitor plasma concentrations of the supplemented anti-
oxidant. Measurement of drug levels in tissues where the dis-
ease process is to bemodified by the drug is not always practical
(e.g., the central nervous system, heart) and target engagement
biomarkers may be more helpful. Nevertheless, even in these
cases, plasma levels of the drug serve important purposes, such
as determination of drug safety and effective drug range.
Thus, it is possible that the lack of response had pharma-
cokinetic rather than pharmacodynamic reasons. In the Eu-
ropean Prospective Investigation into Cancer (EPIC)-Norfolk
study, vitamin C concentrations correlated with lower risk of
all-cause mortality (77) and, in a meta-analysis of prospective
studies, with a lower risk of stroke (25).
According to meta-analyses, long-term, high-dose N-
acetylcysteine (NAC) treatment may improve the clinical
complications of patients with chronic obstructive pulmonary
disease (134) and the prophylactic use of NAC could reduce
the incidence of postoperative atrial fibrillation and all-cause
mortality in adult patients undergoing cardiac surgery (87).
However, apart from a possible publication bias, such non-
interventional observational studies and correlations cannot
establish cause–effect relationships.
Other reasons for the failure of chronic oral antioxidant
therapy may include the slow reaction constants between
superoxide and vitamins C and E (3.3 · 105 and 4.9 · 103 m-
1s-1, respectively, compared with 1.9 · 1010 mol-1 s-1 for the
reaction constant between NO and superoxide) (141).
Moreover, the inclusion criteria for patients can never be as
restrictive as in preclinical studies, and in some cases, the
disease may be at different stages of progression or clinical
manifestation. In addition, as indicated before, in most cases,
chronic, oral vitamin treatment has not been monitored con-
sistently to provide plasma level concentrations or changes in
target engagement biomarkers.
The differences between preclinical stages and clinical
settings are also affected by differences in the antioxidant
drug’s mechanism of action and especially due to pharma-
cokinetic and pharmacodynamic constraints (11). This is best
exemplified with compounds that need to cross the blood–
brain barrier (73).
Finally, it is interesting to note that basic research is biased
by the lack of publications with negative results while most
outcomes of clinical trials are reported. Therefore, it is pos-
sible that this paradox is due, in part, to an under-
representation of the real outcomes in preclinical studies.
Nonredox mechanisms of antioxidants
In other cases, the action of compounds with antioxidant
activity may actually involve nonredox mechanisms, such as
intercalation of DNA and/or inhibition of topoisomerase,
DNA polymerase, and ribonucleotide reductase (40). Flavo-
noids and other phytochemicals can bind to functionally di-
verse cellular targets and this may modulate the activity of a
large number of downstream genes (4).
Ongoing Development of Direct Antioxidants
Figure 4 depicts some conceptual strategies used to block
the imbalanced production of ROS. Despite the failures
and concerns with the use of antioxidant therapy, there are
still several clinical studies and developments ongoing to
translate the direct antioxidant principle into the clinic.
Most of the antioxidant therapies so far utilized compounds
that donate either one or two electrons, which require high
Exercise Oxidative
stress
PGC1
Mitochondrial
biogenesis
Endogenous
antioxidants
and HSPs
Hypertrophy
MAPK NF B
P70S6K
Exercise-induced
bronchoconstriction
(vitamin C)?
Cold symptoms?
(vitamin C)
Fatigability?
(N-acetylcysteine)
Recovery?
(polyphenols)
Possible
beneficial effects
Possible
adverse effects
Antioxidant
supplementation
FIG. 3. Simplified scheme of antioxidant supplementa-
tion outcomes in exercising individuals. Possible adverse
effects are linked to blunted cell signaling and adaptation to
exercise by reducing oxidative stress. The adaptations will de-
pend on the exercise mode (endurance vs. strength), but
MAPKsmay be important signaling proteins (65). The possible
positive effects could not only be linked to the exercised
muscles (reduced fatigability and improved recovery) but also
the upper respiratory system by alleviating common cold
symptoms and exercise-induced bronchoconstriction (10, 51,
52, 101). HSP, heat shock proteins (e.g., HSP70); JNK, c-Jun
N-terminal kinases; MAPK, mitogen-activated protein kinases
(p38, ERK1/2 and JNK); NFjB, nuclear factor kappa B (tran-
scriptions factor); PGC1a, peroxisome proliferator-activated
receptor gamma coactivator 1-alpha. Endogenous antioxidants
include superoxide dismutase, catalase, and glutathione per-
oxidase. To see this illustration in color, the reader is referred to
the web version of this article at www.liebertpub.com/ars
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concentrations and impose the risk of converting the anti-
oxidant into a pro-oxidant. To allow for lower doses, one
alternative approach is to use compounds that are recycled by
cellular reductases or act catalytically (90).
Recycling antioxidants
Ascorbate typically reacts with free radicals, producing an
ascorbyl radical intermediate that may be reduced back or un-
dergo further oxidation to dehydroascorbic acid, for which
specific reductases exist (86). Other recycling antioxidants in-
clude low-molecular-weight thiols (e.g., glutathione and acet-
ylcysteine), thioethers (e.g.,methionine), andmanymore. In the
case of vitamin E (a-tocopherol, in which case recycling de-
pends on nonenzymatic reactions), BO-653 was developed as a
synthetic, improved vitamin E-like molecule for the treatment
of cardiovascular disease (intimal hyperplasia), but it failed in
clinical trials (28). Other examples are the above-mentioned
synthetic antioxidant NXY-059 that failed to improve outcomes
in stroke patients (135) or coenzyme Q10, which failed to im-
prove prognosis of patients with Huntington’s disease (61b).
The glutathione peroxidase mimetic, ebselen (2-phenyl-
1,2-benzoisoselenazol-3(2H)-one), was once considered a
promising synthetic antioxidant since it reacts rapidly with
peroxides (106, 153) and peroxynitrite (98), preventing lipid
peroxidation and oxidative damage of other biomolecules.
However, ebselen failed due to severe liver toxicity and in-
hibition of thiol-dependent enzymes (29). Compounds with a
metal center such as SOD or catalase can in principle detoxify
O2
- and H2O2 in a catalytic manner.
Trace elements such as zinc and selenium may augment
antioxidant enzyme activity, but it will be difficult to ascribe
their beneficial properties to modulating oxidative stress and
not to other effects related to their function as cofactors of
nonredox proteins. Metal porphyrins (FeTMPyP, FeTMPS,
MnTBAP) were not only developed as SOD mimetics
(61, 115) but unfortunately also showed pro-oxidative ac-
tivities in biological systems and, so far, have not reached the
stage of clinical application.
A possible alternative includes mitochondria-targeted
SOD mimetics, for example, Mn(III) 5,10,15,20-tetrakis(N-
methylpyridinium-2-yl)porphyrin (MnTM-2-PyP(5+)) (7, 8),
or the so-called next-generation SODmimetics. This compound
class includes Mn-pentaazamacrocycles such as GC4403 (6,
128). This and other members of the Mn-pentaazamacrocyclic
ligand class of SOD mimetics function by a one-electron redox
cycle, with oxidation of Mn(II) being the rate-determining
step (6).
In animal models of oxidative stress caused by total body
irradiation, GC4403 increased survival, decreased intestinal
apoptosis, protected lymphoid and hematopoietic tissues
(143), and reduced the incidence and severity of radiation-
induced mucositis (108). A related compound, GC4419, is
currently in Phase IIa testing (NCT01921426) in patients
undergoing standard chemoradiation treatment of head and
neck cancer, a setting in which up to 80% of patients develop
severe oral mucositis.
Mitochondria-targeted antioxidants
The direct and specific targeting of mitochondrial ROS
formation by mitochondria-targeted antioxidants is another
strategy still pursued to date. This will decrease mitochondrial
ROS and prevent oxidative damage of important mitochon-
drial structures from ROS produced by extramitochondrial
sources (e.g., mitochondrial DNA is not well protected since
efficient DNA repair systems do not exist in the matrix).
One of the first examples for this class of compounds was
mitoquinone (1, 80), a quinone coupled to triphenylpho-
sphonium, leading to significant accumulation in mitochon-
dria. mitoTEMPO is another promising candidate for
targeting mitochondrial ROS as it prevents adverse effects of
angiotensin-II in experimental hypertension (30). A draw-
back of this strategy could be that these compounds require
viable mitochondria with a certain membrane potential for
uptake, which could limit their accumulation and accordingly
antioxidant potency, especially in dysfunctional ROS-
producing mitochondria. Several candidates of these
mitochondria-targeted antioxidants are currently in late-
phase clinical trials (109, 138).
Pharmacokinetic targeting
Another clinical approach to overcome the limitations or
lack of evidence of chronic oral antioxidant therapy is the
short-term infusion of antioxidants such as vitamin C. Positive
reports include the reduction of histamine levels in allergy
(45), enhanced hearing recovery in idiopathic sudden hearing
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FIG. 4. Conceptual approach to
the use of small molecules as direct
and indirect antioxidants. The
main sources of ROS production in-
clude NOX, mitochondria, xanthine
oxidase, and other enzymes. Direct
antioxidants (green) react with ROS
and, if properly handled, may de-
crease oxidative stress. Indirect an-
tioxidants (orange) activate cellular
antioxidant defenses, such as NRF2-
mediated gene transcription, and
provide a supplemental enzymatic
armamentarium to maintain redox
homeostasis. To see this illustration
in color, the reader is referred to the
web version of this article at www
.liebertpub.com/ars
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loss (74), anti-inflammation improved recovery and lower rate
of complication in pancreatitis (35), reduction of postzoster
neuralgia (130), and reduction of gastrointestinal symptoms,
fatigue, and pain in advanced cancer (22). The mechanistic
rational is that such acute parenteral treatment targets massive
inflammation-associated ROS generation and any side effects
due to interference with physiological functions of ROS, such
as in chronic oral therapy, are not observed.
A recent phase-I study investigating primarily safety of
high-dose vitamin C infusion reported also positive effects on
inflammation and endothelial function (39). However, en-
dothelial function is only a surrogate parameter and hard
outcome studies need to show true patient-relevant benefit.
Prospective studies investigating the intravenous application
of vitamin C in surgery and burn patients reported improved
organ protection and function (83, 119, 142). On the other
hand, preclinical studies prove that pharmacologic vitamin C
concentrations are cytotoxic for cancer cell lines through the
generation of H2O2.
There appears to be a multifactorial process where vitamin
C induces cell cycle arrest, autophagy, apoptosis, and ne-
crosis, depending on the cell genotype, the ascorbate con-
centration, and exposure time (113). The high (millimolar)
concentrations necessary for this tumor cytotoxic effect can
only be achieved intravenously because oral administration
of vitamin C does not increase plasma levels above approx.
0.22mM (84). There are currently three phase I/IIa studies
being carried out in conjunction with the National Institutes
of Health, which examine the effects of high-dosage vitamin
C infusions adjuvant to standard therapy in the case of ad-
vanced tumors (93, 104, 152).
New Indirect Antioxidant Approaches
A different concept to antioxidant therapy follows the
proposition that it is not the antioxidant molecules, but the
antioxidant enzymes that provide relevant therapeutic benefit.
Molecules that augment the physiological antioxidant response
without being antioxidants themselves are here termed indirect
antioxidants and include NRF2 agonists and resveratrol.
NRF2 activators
The transcription factor, nuclear factor (erythroid-derived 2)-
like 2 (NRF2), is a master regulator of cell homeostasis that
regulates the expression of antioxidant and cytoprotective genes
that contain a specific enhancer sequence in their regulatory
regions termed antioxidant response element (ARE). These
genes account for more than 1% of the human genome and
include antioxidant genes,HMOX1 (coding heme oxygenase-1)
and NQO1 (coding NAD(P)H quinone oxidoreductase-1), and
gene encoding enzymes involved in glutathione metabolism or
in the generation of nicotinamide adenine dinucleotide phos-
phate (NADPH), etc. (Fig. 5A). For a detailed catalog of NRF2-
regulated genes, see Hayes and Dinkova-Kostova (48).
Modulation of NRF2 activity may provide two advantages
over direct antioxidants. First, the induction of NADPH,
GSH, and thioredoxin metabolism is a natural system, re-
sulting possibly in antioxidant activity in places where nee-
ded while leaving physiological ROS signaling intact.
Second, because proteins have a longer half-life than small-
molecule activators, the effect on the antioxidant defense
may be more prolonged.
The main mechanism of regulation of NRF2 stability is its
binding to the E3 ligase adapter kelch-like ECH-associated
protein 1 (KEAP1) (Fig. 5B). This protein targets NRF2 for
Cullin3/Rbx-mediated ubiquitination and subsequent pro-
teasomal degradation. However, a drop in GSH concentration
(characteristic of oxidant attack) or the presence of electro-
philes leads to sulfhydryl bonding or adduct formation, re-
spectively. This affects several cysteine residues in KEAP1,
among which C151, C273, and C288 appear to be the most
sensitive, probably because their pKa value is lower (pKa
4–5) compared with other cysteine residues (pKa 8.5) (21,
91). Such modification of KEAP1 leads to disruption of its
interaction with NRF2, its stabilization, nuclear transloca-
tion, and activation of about 250 ARE-containing genes.
All NRF2 agonists modify the sulfhydryl group of cysteine
residues of KEAP1 by oxidation or adduct formation. These
molecules include allyl sulfides, dithiolethiones, flavonoids,
isothiocyanates, polyphenols, and terpenoids (49). However,
electrophilic compounds may also react with redox-sensitive
cysteine residues present in the catalytic center of several
phosphatases. This interaction leads to upregulation of
signaling pathways that further impinge on NRF2 activa-
tion. For instance, carnosol (96), tert-butylhydroquinone
(127), synthetic triterpenoids (2-cyano-3,12-dioxooleana-
1,9-dien-28-oic acid-imidazolide [CDDO; CDDO-Im]) (120),
or nordihydroguaiaretic acid (126) activate AKT signaling.
Several reports demonstrate that phosphatase and tensin
homolog (PTEN), which is mutated in a large number of
human tumors, is a redox-sensitive phosphatase (78). Im-
portantly, the catalytic C124 of PTEN can be modified
through adduct formation with strong electrophiles such as
CDDO-Im (120) and tert-buthylhydroquinone (127). This
modification results in loss of its lipid phosphatase activity
and yields a more sustained activation of signaling events
downstream of PI3K. These events include the activation of
NRF2 by preventing its degradation through a KEAP1-
independent mechanism that involves its phosphorylation by
glycogen synthase-3 and further ubiquitination by a b-TrCP/
Cullin1/Rbx complex (Fig. 5C) (122, 123).
In summary, when considering electrophilic targeting to
NRF2, it is important to remember that not only KEAP1 but
also other redox-sensitive enzymes may cooperate to regulate
this antioxidant pathway.
The most compelling evidence in favor of a role of NRF2 in
prevention or protection from disease has been gathered from
results obtained with NRF2 knockout mice. With increasing
age, these mice present with chronic pathologies related to
oxidant and inflammatory stress, including cognitive deficits
(66), depressive disorder (97), and increased incidence of
lupus-like autoimmune nephritis (92). In humans, many single-
nucleotide polymorphisms have been identified in the coding
and noncoding regions of the gene encoding NRF2, NFE2L2,
and epidemiological studies have revealed significant associa-
tions of NFE2L2 haplotypes with risks in pulmonary, gastro-
intestinal, autoimmune, and neurodegenerative diseases (27).
The most successful case reported so far of an indirect
antioxidant targeting NRF2 is the ester derivative of fumaric
acid, dimethyl fumarate (DMF). DMF crosses the gastroin-
testinal barrier, after which it is converted into the active
principle monomethyl fumarate (MMF), which binds
KEAP1. This binding disrupts the KEAP1/NRF2 interaction
and leads to upregulation of the transcriptional NRF2
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signature of antioxidant genes. Topical and oral administra-
tion of DMF (as a salt solution commercialized as Fuma-
derm) was indicated as early as year 1994 for the treatment of
psoriasis before psoriasis was known to be an autoimmune
disease or the molecular targets of DMF were identified (3).
The immunomodulatory effect of DMF has been exploited
more recently for other autoimmune diseases such as lupus
erythematosus (146), asthma, and arthritis (131), and a
pharmaceutical formulation of DMF, termed FP187, is under
development for use in autoimmune diseases.
DMF is being used in the treatment of relapsing–remitting
multiple sclerosis (MS) (16). MMF is more potent than DMF
in NRF2 activation, but the former is probably metabolized
more rapidly. In an attempt to allow DMF to bypass gastric
metabolism, it has been packaged in an oral delayed-release
formulation known as BG-12. Following the success with
BG-12 in two clinical trials, CONFIRM and DEFINE, this
formulation has been commercialized as Tecfidera (16). Fi-
nally, a new formulation of MMF as a prodrug is currently in
phase I trial for MS (61a).
Other lines of research have focused on targeting NRF2 in
degenerative diseases with low-grade chronic inflammation
using very potent synthetic triterpenoids that target KEAP1/
NRF2. One of these compounds, CDDO-methyl ester (also
known as bardoxolone methyl), was studied for therapy of
diabetic nephropathy (151). The initial excitement about this
compound was hampered by the observation that in the phase
III clinical trial, termed BEACON, there was a small yet
significant increase in heart failure in the treated arm com-
pared with the placebo arm. This drawback was not related to
NRF2 targeting, but rather to alteration of the endothelin
signaling, leading to reduction in urine volume and sodium
excretion in some patients with advanced chronic kidney
disease (26). As a result, bardoxolone methyl is now being
tested in pulmonary arterial hypertension (27a, 60), mela-
noma (54), and Friedreich’s ataxia (27b). Moreover, its safety
and efficacy for chronic kidney disease are being reevaluated
(81a).
A third NRF2-activating principle is the isothiocyanate
sulforaphane. Sulforaphane has been isolated from 3-day-old
broccoli sprouts and other cruciferous vegetables as a product
of the enzymatic cleavage of the glucosinolate, glucor-
aphanin, by the plant enzyme, myrosinase (37). Due to its
electrophilic structure, sulforaphane interacts with specific
FIG. 5. Scheme on the antioxidant potential of the NRF2 signaling pathway and its pharmacologic targeting. (A)
NRF2 is a basic region leucine zipper (bZip) transcription factor that makes dimers with proteins of the small MAF family.
These heterodimers recognize an antioxidant response element (ARE) in about 250 genes (48). The consensus sequence is
taken from JASPAR (99) (B) Regulation of NRF2/KEAP1 by electrophilic compounds. Under basal homeostatic conditions,
NRF2 binds a KEAP1 homodimer through two tethering sites of low affinity (DLG) and high affinity (ETGE) located at the Neh2
domain. KEAP1 is a redox-sensitive E3 ligase adapter that leads to Cul3/Rbx-mediated ubiquitination of NRF2 and subsequent
degradation by the proteasome. Adduct formation with electrophiles induces a conformational change in KEAP1 that prevents
further degradation of NRF2 (145). (C) Regulation of NRF2/PTEN by electrophilic compounds. The lipid phosphatase activity
of PTEN eliminates 3-phosphoinositides required to activate AKT, thus yielding glycogen synthase kinase-3 (GSK-3) active.
GSK-3 phosphorylates NRF2 in several residues (DSGIS) of the Neh6 domain and creates a phosphodegron that is recognized by
the E3 ligase adapter, b-TrCP. This process leads to a Cul1/Rbx-mediated ubiquitination and further proteasome degradation of
NRF2. However, some electrophiles react with the critical C124 residue of PTEN located at the catalytic center to inhibit this
enzyme. Then, 3-phosphoinositide levels remain high, leading to enhanced activation of AKT and inhibition of GSK-3. Under
these conditions, NRF2 escapes GSK-3-mediated phosphorylation and recognition by the b-TrCP/Cul1/Rbx ubiquitin ligase
(123, 127). AKT, protein kinase B; KEAP1, kelch-like ECH-associated protein 1; PTEN, phosphatase and tensin homolog. To
see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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redox-sensitive cysteine residues in KEAP1, including
Cys151. This disrupts the Keap1/NRF2 complex and leads to
the increase in NRF2 protein levels and transcriptional ac-
tivity (31). Most clinical studies performed with sulforaphane
have used a highly standardized formulation of broccoli
sprout extracts. In contrast to DMF and bardoxolone methyl,
a drawback of sulforaphane is the absence of a pure formu-
lation that could be used clinically and the lack of commer-
cial value that could attract the strong investment that
pipelines on drug development require. Nevertheless, several
attempts are being made to provide proof of concept that
NRF2 targeting with sulforaphane has a therapeutic value.
Currently, at least 32 studies assess its clinical efficacy in
chronic diseases such as cancer, asthma, autism, schizo-
phrenia, chronic kidney disease, type 2 diabetes, and cystic
fibrosis.
Resveratrol
A comprehensive overview about resveratrol, including its
targets and findings in clinical trials, is provided in a recent
review (23) and schematized in Figure 6. The antioxidant
phytochemical resveratrol was initially viewed as a direct
ROS scavenger, but recent data suggest that its beneficial
effects—if any—are rather mediated by indirect antioxidant
mechanisms (85). Resveratrol increases the expression of
antioxidant enzymes, such as SODs, catalase, glutathione
peroxidase, and others, and reduces the expression of the
ROS-forming NADPH oxidase type 4 (NOX4) (139).
In addition, resveratrol confers antioxidant activity by in-
duction of the NRF2-heme oxygenase-1 pathway (69, 70) and
it restores the activity of eNOS by increasing the synthesis of
its cofactor, tetrahydrobiopterin (BH4) (155). There is also
good evidence that resveratrol not only acts on gene ex-
pression via miRNAs as well as epigenetic modifications via
activation of the NAD+-dependent deacetylase sirtuin 1
(SIRT1) (38, 85, 105) but also on proteins of the DNA repair
machinery, thereby contributing to genome stability (41).
The most compelling clinical studies on the use of
resveratrol in antioxidant therapy have demonstrated a re-
duction in redox biomarkers together with an increase in the
NRF2 signature (42). In some cases, preliminary evidence of
a salutary effect has been reported. Thus, resveratrol im-
proves insulin sensitivity in patients with type 2 diabetes (19).
In obese humans, resveratrol supplementation induced met-
abolic changes mimicking the effects of calorie restriction
(144). Resveratrol demonstrated anti-inflammatory, antioxi-
dant, and hypotriglyceridemic effects in healthy smokers
(15). Further phase III studies will be required to determine
real efficacy of this indirect antioxidant.
Conclusions
In view of the disparate results obtained with antioxidant
compounds ranging from possibly beneficial to many futile to
some harmful effects, it is necessary to reevaluate antioxidant
therapy with a revised concept of oxidative stress that con-
siders not only over ROS imbalance in a quantitative manner
but also the molecular nature of ROS local cellular and tissue
production and the enzymatic machinery in charge of its
regulation.
While chronic, not indicated, therapy with antioxidants
(especially lipid-soluble ones) must clearly not be re-
commended, there may be potential for the use of selective
antioxidants, such as vitamin C, in situations of deficiencies
or short-term overproduction accessible to parenteral high-
dose therapy. Whether there is room for SODmimetics needs
to be shown.
More modern indirect antioxidants that target redox en-
zymes seem to be the more promising. NRF2 agonists may
have the benefit of not causing reductive stress, but instead to
upregulate endogenous antioxidant defense systems. Other
approaches such as interfering with specific ROS-producing
enzymes directly or even functionally repairing ROS-induced
damage are discussed in another review of this Forum (see
Targets review in the same Forum). Time and clinical trials
investigating patient-relevant outcomes will tell.
Acknowledgments
A.C. is the recipient of a research grant, SAF2013-43271-
R, from the Spanish Ministry of Economy and Competi-
tiveness. A.D. was supported by grants by the Federal
Ministry of Education and Research to the Center of
Thrombosis and Hemostasis Mainz (BMBF 01EO1003). R.S.
is the recipient of a Senior Principal Research Fellowship of
the National Health and Medical Research Council of Aus-
tralia. Several authors of this review were supported by the
European Cooperation in Science and Technology (COST
Action BM1203/EU-ROS).
Author Disclosure Statement
Claudia Vollbracht is a part-time employee of Pascoe
Pharmazeutische Pra¨parate GmbH, Giessen, Germany, which
markets parenteral vitamin C products. Dennis Riley is the
Chief Scientific Officer of Galera Therapeutics, Inc. (Malvern,
PA), which is developing GC4419, an SOD mimetic. For all
other authors, no competing financial interests exist.
FIG. 6. Two mechanisms used by resveratrol to pro-
vide oxidant protection. SIRT1 is a histone deacetylase
that participates in chromatin remodeling (not shown) and
also in post-translational modification of transcription fac-
tors, such as PGC-1a, FOXO3a, and NF-jB. In addition, it
inhibits KEAP1 and leads to NRF2 activation. To see this
illustration in color, the reader is referred to the web version
of this article at www.liebertpub.com/ars
ANTIOXIDANTS IN TRANSLATIONAL MEDICINE 1137
References
1. Adlam VJ, Harrison JC, Porteous CM, James AM, Smith
RA, Murphy MP, and Sammut IA. Targeting an antioxi-
dant to mitochondria decreases cardiac ischemia-
reperfusion injury. FASEB J 19: 1088–1095, 2005.
2. Ali-Hassan-Sayegh S, Mirhosseini SJ, Rezaeisadrabadi M,
Dehghan HR, Sedaghat-Hamedani F, Kayvanpour E, Po-
pov AF, and Liakopoulos OJ. Antioxidant supplementa-
tions for prevention of atrial fibrillation after cardiac
surgery: an updated comprehensive systematic review and
meta-analysis of 23 randomized controlled trials. Interact
Cardiovasc Thorac Surg 18: 646–654, 2014.
3. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch
PJ, Ruppert P, Wassilew SW, Horn T, Kreysel HW, Lutz
G, et al. Antipsoriatic effect of fumaric acid derivatives.
Results of a multicenter double-blind study in 100 pa-
tients. J Am Acad Dermatol 30: 977–981, 1994.
4. Arango D, Morohashi K, Yilmaz A, Kuramochi K, Parihar
A, Brahimaj B, Grotewold E, and Doseff AI. Molecular
basis for the action of a dietary flavonoid revealed by the
comprehensive identification of apigenin human targets.
Proc Natl Acad Sci U S A 110: E2153–E2162, 2013.
5. Ashor AW, Lara J, Mathers JC, and Siervo M. Effect of
vitamin C on endothelial function in health and disease: a
systematic review and meta-analysis of randomised con-
trolled trials. Atherosclerosis 235: 9–20, 2014.
6. Aston K, Rath N, Naik A, Slomczynska U, Schall OF, and
Riley DP. Computer-aided design (CAD) of Mn(II)
complexes: superoxide dismutase mimetics with catalytic
activity exceeding the native enzyme. Inorg Chem 40:
1779–1789, 2001.
7. Batinic-Haberle I, Rajic Z, Tovmasyan A, Reboucas JS,
Ye X, Leong KW, Dewhirst MW, Vujaskovic Z, Benov L,
and Spasojevic I. Diverse functions of cationic Mn(III) N-
substituted pyridylporphyrins, recognized as SOD mimics.
Free Radic Biol Med 51: 1035–1053, 2011.
8. Batinic-Haberle I, Tovmasyan A, Roberts ER, Vujaskovic
Z, Leong KW, and Spasojevic I. SOD therapeutics: latest
insights into their structure-activity relationships and im-
pact on the cellular redox-based signaling pathways. An-
tioxid Redox Signal 20: 2372–2415, 2014.
9. Bauersachs J and Widder JD. Reductive stress: linking
heat shock protein 27, glutathione, and cardiomyopathy?
Hypertension 55: 1299–1300, 2010.
10. Bell PG, McHugh MP, Stevenson E, and Howatson G.
The role of cherries in exercise and health. Scand J Med
Sci Sports 24: 477–490, 2014.
11. Benfeito S, Oliveira C, Soares P, Fernandes C, Silva T,
Teixeira J, and Borges F. Antioxidant therapy: still in
search of the ‘magic bullet’. Mitochondrion 13: 427–435,
2013.
12. Benhar M and Stamler JS. A central role for S-
nitrosylation in apoptosis. Nat Cell Biol 7: 645–646, 2005.
13. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, and
Gluud C. Mortality in randomized trials of antioxidant sup-
plements for primary and secondary prevention: systematic
review and meta-analysis. JAMA 297: 842–857, 2007.
14. Bjelakovic G, Nikolova D, Simonetti RG, and Gluud C.
Antioxidant supplements for prevention of gastrointestinal
cancers: a systematic review and meta-analysis. Lancet
364: 1219–1228, 2004.
15. Bo S, Ciccone G, Castiglione A, Gambino R, De Michieli
F, Villois P, Durazzo M, Cavallo-Perin P, and Cassader
M. Anti-inflammatory and antioxidant effects of resvera-
trol in healthy smokers a randomized, double-blind,
placebo-controlled, cross-over trial. Curr Med Chem 20:
1323–1331, 2013.
16. Bomprezzi R. Dimethyl fumarate in the treatment of
relapsing-remitting multiple sclerosis: an overview. Ther
Adv Neurol Disord 8: 20–30, 2015.
17. Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR,
Yusuf S, and Investigators HH-TS. Long-term effects of
ramipril on cardiovascular events and on diabetes: results
of the HOPE study extension. Circulation 112: 1339–
1346, 2005.
18. Braakhuis AJ and Hopkins WG. Impact of dietary anti-
oxidants on sport performance: a review. Sports Med 45:
939–955, 2015.
19. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B,
Cseh J, Mikolas E, Szijarto IA, Merei A, Halmai R,
Meszaros LG, Sumegi B, and Wittmann I. Resveratrol
improves insulin sensitivity, reduces oxidative stress and
activates the Akt pathway in type 2 diabetic patients. Br J
Nutr 106: 383–389, 2011.
20. Brown DI and Griendling KK. Regulation of signal
transduction by reactive oxygen species in the cardio-
vascular system. Circ Res 116: 531–549, 2015.
21. Bryan HK, Olayanju A, Goldring CE, and Park BK. The
Nrf2 cell defence pathway: Keap1-dependent and
-independent mechanisms of regulation. Biochem
Pharmacol 85: 705–717, 2013.
22. Carr AC, Vissers MC, and Cook JS. The effect of intra-
venous vitamin C on cancer- and chemotherapy-related
fatigue and quality of life. Front Oncol 4: 283, 2014.
23. Carrizzo A, Forte M, Damato A, Trimarco V, Salzano F,
Bartolo M, Maciag A, Puca AA, and Vecchione C. Anti-
oxidant effects of resveratrol in cardiovascular, cerebral and
metabolic diseases. Food Chem Toxicol 61: 215–226, 2013.
24. Chen AF, Chen DD, Daiber A, Faraci FM, Li H, Rembold
CM, and Laher I. Free radical biology of the cardiovas-
cular system. Clin Sci (Lond) 123: 73–91, 2012.
25. Chen GC, Lu DB, Pang Z, and Liu QF. Vitamin C intake,
circulating vitamin C and risk of stroke: a meta-analysis of
prospective studies. J Am Heart Assoc 2: e000329, 2013.
26. Chin MP, Reisman SA, Bakris GL, O’Grady M, Linde PG,
McCullough PA, Packham D, Vaziri ND, Ward KW, War-
nock DG, and Meyer CJ. Mechanisms contributing to ad-
verse cardiovascular events in patients with type 2 diabetes
mellitus and stage 4 chronic kidney disease treated with
bardoxolone methyl. Am J Nephrol 39: 499–508, 2014.
27. Cho HY. Genomic structure and variation of nuclear
factor (erythroid-derived 2)-like 2. Oxid Med Cell Longev
2013: 286524, 2013.
27a. Clinicaltrials.gov. 2015. Bardoxolone Methyl Evaluation in
Patients With Pulmonary Arterial Hypertension (PAH)–
LARIAT. https://clinicaltrials.gov/ct2/show/NCT02036970.
Accessed August 2015.
27b. Clinicaltrials.gov. 2015. RTA 408 Capsules in Patients
With Friedreich’s Ataxia–MOXIe. https://clinicaltrials
.gov/ct2/show/NCT02255435. Accessed August 2015.
28. Cynshi O, Kawabe Y, Suzuki T, Takashima Y, Kaise H,
Nakamura M, Ohba Y, Kato Y, Tamura K, Hayasaka A,
Higashida A, Sakaguchi H, Takeya M, Takahashi K, In-
oue K, Noguchi N, Niki E, and Kodama T. Anti-
atherogenic effects of the antioxidant BO-653 in three
different animal models. Proc Natl Acad Sci U S A 95:
10123–10128, 1998.
1138 SCHMIDT ET AL.
29. Daiber A, Zou MH, Bachschmid M, and Ullrich V. Eb-
selen as a peroxynitrite scavenger in vitro and ex vivo.
Biochem Pharmacol 59: 153–160, 2000.
30. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR,
McCann L, Lewis W, Harrison DG, and Dikalov SI.
Therapeutic targeting of mitochondrial superoxide in hy-
pertension. Circ Res 107: 106–116, 2010.
31. Dinkova-Kostova AT and Talalay P. Direct and indirect
antioxidant properties of inducers of cytoprotective pro-
teins. Mol Nutr Food Res 52 Suppl 1: S128–S138, 2008.
32. Donko A, Morand S, Korzeniowska A, Boudreau HE,
Zana M, Hunyady L, Geiszt M, and Leto TL.
Hypothyroidism-associated missense mutation impairs
NADPH oxidase activity and intracellular trafficking of
Duox2. Free Radic Biol Med 73: 190–200, 2014.
33. Dotan Y, Pinchuk I, Lichtenberg D, and Leshno M. De-
cision analysis supports the paradigm that indiscriminate
supplementation of vitamin E does more harm than good.
Arterioscler Thromb Vasc Biol 29: 1304–1309, 2009.
34. Drummond GR, Cai H, Davis ME, Ramasamy S, and
Harrison DG. Transcriptional and posttranscriptional
regulation of endothelial nitric oxide synthase expression
by hydrogen peroxide. Circ Res 86: 347–354, 2000.
35. Du WD, Yuan ZR, Sun J, Tang JX, Cheng AQ, Shen DM,
Huang CJ, Song XH, Yu XF, and Zheng SB. Therapeutic effi-
cacy of high-dose vitamin C on acute pancreatitis and its po-
tentialmechanisms.WorldJGastroenterol9:2565–2569,2003.
36. Eidelman RS, Hollar D, Hebert PR, Lamas GA, and
Hennekens CH. Randomized trials of vitamin E in the
treatment and prevention of cardiovascular disease. Arch
Intern Med 164: 1552–1556, 2004.
37. Fahey JW, Zhang Y, and Talalay P. Broccoli sprouts: an
exceptionally rich source of inducers of enzymes that
protect against chemical carcinogens. Proc Natl Acad Sci
U S A 94: 10367–10372, 1997.
38. Farghali H, Kutinova Canova N, and Lekic N. Resveratrol
and related compounds as antioxidants with an allosteric
mechanism of action in epigenetic drug targets. Physiol
Res 62: 1–13, 2013.
39. Fowler AA, 3rd, Syed AA, Knowlson S, Sculthorpe R,
Farthing D, Dewilde C, Farthing CA, Larus TL, Martin E,
Brophy DF, Gupta S, Fisher BJ, and Natarajan R. Phase I
safety trial of intravenous ascorbic acid in patients with
severe sepsis. J Transl Med 12: 32, 2014.
40. Fox JT, Sakamuru S, Huang R, Teneva N, Simmons SO,
Xia M, Tice RR, Austin CP, and Myung K. High-
throughput genotoxicity assay identifies antioxidants as
inducers of DNA damage response and cell death. Proc
Natl Acad Sci U S A 109: 5423–5428, 2012.
41. Gatz SA and Wiesmuller L. Take a break—resveratrol in
action on DNA. Carcinogenesis 29: 321–332, 2008.
42. Ghanim H, Sia CL, Abuaysheh S, Korzeniewski K,
Patnaik P, Marumganti A, Chaudhuri A, and Dandona P.
An antiinflammatory and reactive oxygen species sup-
pressive effects of an extract of Polygonum cuspidatum
containing resveratrol. J Clin Endocrinol Metab 95: E1–
E8, 2010.
43. Griendling KK and FitzGerald GA. Oxidative stress and
cardiovascular injury: Part II: animal and human studies.
Circulation 108: 2034–2040, 2003.
44. Gustafson CB, Yang C, Dickson KM, Shao H, Van
Booven D, Harbour JW, Liu ZJ, and Wang G. Epigenetic
reprogramming of melanoma cells by vitamin C treat-
ment. Clin Epigenetics 7: 51, 2015.
45. Hagel AF, Layritz CM, Hagel WH, Hagel HJ, Hagel E,
Dauth W, Kressel J, Regnet T, Rosenberg A, Neurath MF,
Molderings GJ, and Raithel M. Intravenous infusion of
ascorbic acid decreases serum histamine concentrations in
patients with allergic and non-allergic diseases. Naunyn
Schmiedebergs Arch Pharmacol 386: 789–793, 2013.
46. Halliwell B. Cell culture, oxidative stress, and antioxi-
dants: avoiding pitfalls. Biomed J 37: 99–105, 2014.
47. Harris HR, Orsini N, and Wolk A. Vitamin C and survival
among women with breast cancer: a meta-analysis. Eur J
Cancer 50: 1223–1231, 2014.
48. Hayes JD and Dinkova-Kostova AT. The Nrf2 regulatory
network provides an interface between redox and interme-
diary metabolism. Trends Biochem Sci 39: 199–218, 2014.
49. Hayes JD, McMahon M, Chowdhry S, and Dinkova-
Kostova AT. Cancer chemoprevention mechanisms me-
diated through the Keap1-Nrf2 pathway. Antioxid Redox
Signal 13: 1713–1748, 2010.
50. Heitzer T, Finckh B, Albers S, Krohn K, Kohlschutter A, and
Meinertz T. Beneficial effects of alpha-lipoic acid and ascor-
bic acid on endothelium-dependent, nitric oxide-mediated
vasodilation in diabetic patients: relation to parameters of
oxidative stress. Free Radic Biol Med 31: 53–61, 2001.
51. Hemila H. Vitamin C may alleviate exercise-induced
bronchoconstriction: ameta-analysis.BMJOpen 3: e002416,
2013.
52. Hemila H and Chalker E. Vitamin C for preventing and
treating the common cold. Cochrane Database Syst Rev 1:
CD000980, 2013.
53. Henry PT and Chandy MJ. Effect of ascorbic acid on
infarct size in experimental focal cerebral ischaemia and
reperfusion in a primate model. Acta Neurochir (Wien)
140: 977–980, 1998.
54. Hong DS, Kurzrock R, Supko JG, He X, Naing A,Wheler J,
Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J,
KonoplevaM, Konoplev S, Andreeff M, Kufe D, Lazarus H,
Shapiro GI, and Dezube BJ. A phase I first-in-human trial of
bardoxolone methyl in patients with advanced solid tumors
and lymphomas. Clin Cancer Res 18: 3396–3406, 2012.
55. This reference has been deleted.
56. This reference has been deleted.
57. This reference has been deleted.
58. This reference has been deleted.
59. This reference has been deleted.
60. Hu J, Xu Q, McTiernan C, Lai YC, Osei-Hwedieh D, and
Gladwin M. Novel targets of drug treatment for pulmo-
nary hypertension. Am J Cardiovasc Drugs 15: 225–234,
2015.
61. Hunt JA, Lee J, and Groves JT. Amphiphilic peroxynitrite
decomposition catalysts in liposomal assemblies. Chem
Biol 4: 845–858, 1997.
61a. Hunt TL, Durairaj C, Leigh-Pemberton R, Jiang Y,
Manthis J, and Hard M. 2015 Safety, Tolerability, and
Pharmacokinetics of ALKS 8700, a Novel Oral Therapy
for Relapsing-RemittingMultiple Sclerosis, in Healthy
Subjects. The 2015 Annual Meeting of the Consortium of
Multiple Sclerosis Centers (CMSC). http://annualmeeting
.mscare.org/ Accessed August 2015.
61b. Huntington Study Group. 2014. Announcement of
2CARE Early Study Closure. http://huntingtonstudygroup
.org/tag/2care/. Accessed August 2015.
62. Ischiropoulos H and Beckman JS. Oxidative stress and
nitration in neurodegeneration: cause, effect, or associa-
tion? J Clin Invest 111: 163–169, 2003.
ANTIOXIDANTS IN TRANSLATIONAL MEDICINE 1139
63. Ishihara O, Hayashi M, Osawa H, Kobayashi K, Takeda S,
Vessby B, and Basu S. Isoprostanes, prostaglandins and
tocopherols in pre-eclampsia, normal pregnancy and non-
pregnancy. Free Radic Res 38: 913–918, 2004.
64. Jackson MJ. Redox regulation of adaptive responses in
skeletal muscle to contractile activity. Free Radic Biol
Med 47: 1267–1275, 2009.
65. Ji LL. Antioxidant signaling in skeletal muscle: a brief
review. Exp Gerontol 42: 582–593, 2007.
66. Jo C, Gundemir S, Pritchard S, Jin YN, Rahman I, and
Johnson GV. Nrf2 reduces levels of phosphorylated tau
protein by inducing autophagy adaptor protein NDP52.
Nat Commun 5: 3496, 2014.
67. Johnson BD, Mather KJ, Newcomer SC, Mickleborough
TD, and Wallace JP. Vitamin C prevents the acute decline
of flow-mediated dilation after altered shear rate patterns.
Appl Physiol Nutr Metab 38: 268–274, 2013.
68. Jones DP and Go YM. Redox compartmentalization and cel-
lular stress.Diabetes Obes Metab 12 Suppl 2: 116–125, 2010.
69. Juan SH, Cheng TH, Lin HC, Chu YL, and Lee WS.
Mechanism of concentration-dependent induction of heme
oxygenase-1 by resveratrol in human aortic smooth mus-
cle cells. Biochem Pharmacol 69: 41–48, 2005.
70. Kaga S, Zhan L, Matsumoto M, and Maulik N. Resvera-
trol enhances neovascularization in the infarcted rat
myocardium through the induction of thioredoxin-1, heme
oxygenase-1 and vascular endothelial growth factor. J Mol
Cell Cardiol 39: 813–822, 2005.
71. Kaiser J. Biomedical research. Antioxidants could spur
tumors by acting on cancer gene. Science 343: 477, 2014.
72. Kajimoto H, Hashimoto K, Bonnet SN, Haromy A, Harry
G, Moudgil R, Nakanishi T, Rebeyka I, Thebaud B, Mi-
chelakis ED, and Archer SL. Oxygen activates the Rho/
Rho-kinase pathway and induces RhoB and ROCK-1 ex-
pression in human and rabbit ductus arteriosus by in-
creasing mitochondria-derived reactive oxygen species: a
newly recognized mechanism for sustaining ductal con-
striction. Circulation 115: 1777–1788, 2007.
73. Kamat CD, Gadal S, Mhatre M, Williamson KS, Pye QN,
and Hensley K. Antioxidants in central nervous system
diseases: preclinical promise and translational challenges.
J Alzheimers Dis 15: 473–493, 2008.
74. Kang HS, Park JJ, Ahn SK, Hur DG, and Kim HY. Effect
of high dose intravenous vitamin C on idiopathic sudden
sensorineural hearing loss: a prospective single-blind
randomized controlled trial. Eur Arch Otorhinolaryngol
270: 2631–2636, 2013.
75. Karbach S, Wenzel P, Waisman A, Munzel T, and Daiber
A. eNOS uncoupling in cardiovascular diseases—the role
of oxidative stress and inflammation. Curr Pharm Des 20:
3579–3594, 2014.
76. Kemp M, Go YM, and Jones DP. Nonequilibrium ther-
modynamics of thiol/disulfide redox systems: a perspec-
tive on redox systems biology. Free Radic Biol Med 44:
921–937, 2008.
77. Khaw KT, Bingham S, Welch A, Luben R, Wareham N,
Oakes S, and Day N. Relation between plasma ascorbic
acid and mortality in men and women in EPIC-Norfolk
prospective study: a prospective population study. Euro-
pean Prospective Investigation into Cancer and Nutrition.
Lancet 357: 657–663, 2001.
78. Kitagishi Y and Matsuda S. Redox regulation of tumor
suppressor PTEN in cancer and aging (Review). Int J Mol
Med 31: 511–515, 2013.
79. Kojo S. Oxygen is the key factor associated with the
difference between in vivo and in vitro effects of antiox-
idants. Proc Natl Acad Sci U S A 109: E2028; author reply
E2029, 2012.
80. Koopman WJ, Verkaart S, Visch HJ, van der Westhuizen
FH, Murphy MP, van den Heuvel LW, Smeitink JA, and
Willems PH. Inhibition of complex I of the electron transport
chain causes O2-. -mediated mitochondrial outgrowth. Am J
Physiol Cell Physiol 288: C1440–C1450, 2005.
81. Kris-Etherton PM, Lichtenstein AH, Howard BV, Steinberg
D, Witztum JL; Nutrition Committee of the American
Heart Association Council on Nutrition, Physical Activity,
and Metabolism. Antioxidant vitamin supplements and
cardiovascular disease. Circulation 110: 637–641, 2004.
81a. Kyowa Hakko Kirin Co, ltd. 2013. Kyowa Hakko Kirin
Announces the Development Status of Bardoxolone Me-
thyl (RTA 402) in Patients with Chronic Kidney Disease
and Type 2 Diabetes in Japan. www.kyowa-kirin.com/
news_releases/2013/e20131111_01.html (Accessed Au-
gust 2015).
82. Lee DH, Folsom AR, Harnack L, Halliwell B, and Jacobs
DR, Jr. Does supplemental vitamin C increase cardio-
vascular disease risk in women with diabetes? Am J Clin
Nutr 80: 1194–1200, 2004.
83. Lee JY, Kim CJ, and Chung MY. Effect of high-dose
vitamin C on oxygen free radical production and myo-
cardial enzyme after tourniquet ischaemia-reperfusion
injury during bilateral total knee replacement. J Int Med
Res 38: 1519–1529, 2010.
84. Levine M, Padayatty SJ, and Espey MG. Vitamin C: a
concentration-function approach yields pharmacology and
therapeutic discoveries. Adv Nutr 2: 78–88, 2011.
85. Li H, Xia N, and Forstermann U. Cardiovascular effects
and molecular targets of resveratrol. Nitric Oxide 26: 102–
110, 2012.
86. Linster CL and Van Schaftingen E. Vitamin C. Bio-
synthesis, recycling and degradation in mammals. FEBS J
274: 1–22, 2007.
87. Liu XH, Xu CY, and Fan GH. Efficacy of N-acetylcysteine
in preventing atrial fibrillation after cardiac surgery: a meta-
analysis of published randomized controlled trials. BMC
Cardiovasc Disord 14: 52, 2014.
88. Lobysheva I, Rath G, Sekkali B, Bouzin C, Feron O, Gallez B,
Dessy C, and Balligand JL. Moderate caveolin-1 down-
regulation prevents NADPH oxidase-dependent endothelial
nitric oxide synthase uncoupling by angiotensin II in endothe-
lial cells.Arterioscler ThrombVasc Biol 31: 2098–2105, 2011.
89. Lonn E, Bosch J, Yusuf S, Sheridan P, Pogue J, Arnold
JM, Ross C, Arnold A, Sleight P, Probstfield J, and Da-
genais GR. Effects of long-term vitamin E supplementa-
tion on cardiovascular events and cancer: a randomized
controlled trial. JAMA 293: 1338–1347, 2005.
90. Lonn ME, Dennis JM, and Stocker R. Actions of ‘‘anti-
oxidants’’ in the protection against atherosclerosis. Free
Radic Biol Med 53: 863–884, 2012.
91. Ma Q. Role of nrf2 in oxidative stress and toxicity. Annu
Rev Pharmacol Toxicol 53: 401–426, 2013.
92. Ma Q, Battelli L, and Hubbs AF. Multiorgan autoimmune
inflammation, enhanced lymphoproliferation, and im-
paired homeostasis of reactive oxygen species in mice
lacking the antioxidant-activated transcription factor Nrf2.
Am J Pathol 168: 1960–1974, 2006.
93. Ma Y, Chapman J, Levine M, Polireddy K, Drisko J,
and Chen Q. High-dose parenteral ascorbate enhanced
1140 SCHMIDT ET AL.
chemosensitivity of ovarian cancer and reduced toxicity of
chemotherapy. Sci Transl Med 6: 222ra18, 2014.
94. Makanae Y, Kawada S, Sasaki K, Nakazato K, and Ishii
N. Vitamin C administration attenuates overload-induced
skeletal muscle hypertrophy in rats. Acta Physiol (Oxf)
208: 57–65, 2013.
95. Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ,
Pogue J, Bosch J, Dagenais GR, and Yusuf S. Effects of
vitamin E on cardiovascular outcomes in people with
mild-to-moderate renal insufficiency: results of the HOPE
study. Kidney Int 65: 1375–1380, 2004.
96. Martin D, Rojo AI, Salinas M, Diaz R, Gallardo G, Alam
J, De Galarreta CM, and Cuadrado A. Regulation of heme
oxygenase-1 expression through the phosphatidylinositol
3-kinase/Akt pathway and the Nrf2 transcription factor in
response to the antioxidant phytochemical carnosol. J Biol
Chem 279: 8919–8929, 2004.
97. Martin-de-Saavedra MD, Budni J, Cunha MP, Gomez-
Rangel V, Lorrio S, Del Barrio L, Lastres-Becker I,
Parada E, Tordera RM, Rodrigues AL, Cuadrado A, and
Lopez MG. Nrf2 participates in depressive disorders
through an anti-inflammatory mechanism. Psychoneur-
oendocrinology 38: 2010–2022, 2013.
98. Masumoto H and Sies H. The reaction of ebselen with
peroxynitrite. Chem Res Toxicol 9: 262–267, 1996.
99. Mathelier A, Zhao X, Zhang AW, Parcy F,Worsley-Hunt R,
Arenillas DJ, Buchman S, Chen CY, Chou A, Ienasescu H,
Lim J, Shyr C, Tan G, Zhou M, Lenhard B, Sandelin A, and
Wasserman WW. JASPAR 2014: an extensively expanded
and updated open-access database of transcription factor
binding profiles. Nucleic Acids Res 42: D142–D147, 2014.
100. Matoba T, Shimokawa H, Nakashima M, Hirakawa Y,
Mukai Y, Hirano K, Kanaide H, and Takeshita A. Hy-
drogen peroxide is an endothelium-derived hyperpolariz-
ing factor in mice. J Clin Invest 106: 1521–1530, 2000.
101. Medved I, Brown MJ, Bjorksten AR, Murphy KT, Pe-
tersen AC, Sostaric S, Gong X, and McKenna MJ. N-
acetylcysteine enhances muscle cysteine and glutathione
availability and attenuates fatigue during prolonged ex-
ercise in endurance-trained individuals. J Appl Physiol
(1985) 97: 1477–1485, 2004.
102. Miller ER, 3rd, Pastor-Barriuso R, Dalal D, Riemersma
RA, Appel LJ, and Guallar E. Meta-analysis: high-dosage
vitamin E supplementation may increase all-cause mor-
tality. Ann Intern Med 142: 37–46, 2005.
103. Mofarrahi M, Brandes RP, Gorlach A, Hanze J, Terada
LS, Quinn MT, Mayaki D, Petrof B, and Hussain SN.
Regulation of proliferation of skeletal muscle precursor
cells by NADPH oxidase. Antioxid Redox Signal 10: 559–
574, 2008.
104. Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G,
Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, and Levine
M. Phase I evaluation of intravenous ascorbic acid in
combination with gemcitabine and erlotinib in patients with
metastatic pancreatic cancer. PLoS One 7: e29794, 2012.
105. Mukhopadhyay P, Pacher P, and Das DK. MicroRNA
signatures of resveratrol in the ischemic heart. Ann N Y
Acad Sci 1215: 109–116, 2011.
106. Muller A, Cadenas E, Graf P, and Sies H. A novel biologi-
cally active seleno-organic compound—I. Glutathione
peroxidase-like activity in vitro and antioxidant capacity of
PZ 51 (Ebselen). Biochem Pharmacol 33: 3235–3239, 1984.
107. Muntwyler J, Hennekens CH, Manson JE, Buring JE, and
Gaziano JM. Vitamin supplement use in a low-risk popu-
lation of US male physicians and subsequent cardiovascular
mortality. Arch Intern Med 162: 1472–1476, 2002.
108. Murphy CK, Fey EG, Watkins BA, Wong V, Rothstein D,
and Sonis ST. Efficacy of superoxide dismutase mimetic
M40403 in attenuating radiation-induced oral mucositis in
hamsters. Clin Cancer Res 14: 4292–4297, 2008.
109. Murphy MP. Antioxidants as therapies: can we improve
on nature? Free Radic Biol Med 66: 20–23, 2014.
110. Nezis IP and Stenmark H. p62 at the interface of autop-
hagy, oxidative stress signaling, and cancer. Antioxid
Redox Signal 17: 786–793, 2012.
111. Paffenholz R, Bergstrom RA, Pasutto F, Wabnitz P,
Munroe RJ, Jagla W, Heinzmann U, Marquardt A, Bareiss
A, Laufs J, Russ A, Stumm G, Schimenti JC, and Berg-
strom DE. Vestibular defects in head-tilt mice result from
mutations in Nox3, encoding an NADPH oxidase. Genes
Dev 18: 486–491, 2004.
112. Palm M, Axelsson O, Wernroth L, and Basu S. F(2)-
isoprostanes, tocopherols and normal pregnancy. Free
Radic Res 43: 546–552, 2009.
113. Parrow NL, Leshin JA, and Levine M. Parenteral ascorbate
as a cancer therapeutic: a reassessment based on pharma-
cokinetics. Antioxid Redox Signal 19: 2141–2156, 2013.
114. Paschalis V, Theodorou AA, Kyparos A, Dipla K, Za-
feiridis A, Panayiotou G, Vrabas IS, and Nikolaidis MG.
Low vitamin C values are linked with decreased physical
performance and increased oxidative stress: reversal by
vitamin C supplementation. Eur J Nutr 2014 [Epub ahead
of print]; DOI: 10.1007/s00394-014-0821-x.
115. Pasternack RF and Skowronek WR, Jr. Catalysis of the
disproportionation of superoxide by metalloporphyrins. J
Inorg Biochem 11: 261–267, 1979.
116. Paulsen G, Cumming KT, Holden G, Hallen J, Ronnestad
BR, Sveen O, Skaug A, Paur I, Bastani NE, Ostgaard HN,
Buer C, Midttun M, Freuchen F, Wiig H, Ulseth ET, Garthe
I, Blomhoff R, Benestad HB, and Raastad T. Vitamin C and
E supplementation hampers cellular adaptation to endur-
ance training in humans: a double-blind, randomised,
controlled trial. J Physiol 592: 1887–1901, 2014.
117. Paulsen G, Hamarsland H, Cumming KT, Johansen RE,
Hulmi JJ, Borsheim E, Wiig H, Garthe I, and Raastad T.
Vitamin C and E supplementation alters protein signalling
after a strength training session, but not muscle growth during
10 weeks of training. J Physiol 592: 5391–5408, 2014.
118. Perera RM and Bardeesy N. Cancer: when antioxidants
are bad. Nature 475: 43–44, 2011.
119. Pignatelli P, Tanzilli G, Carnevale R, Di Santo S, Lof-
fredo L, Celestini A, Proietti M, Tovaglia P, Mangieri E,
Basili S, and Violi F. Ascorbic acid infusion blunts
CD40L upregulation in patients undergoing coronary
stent. Cardiovasc Ther 29: 385–394, 2011.
120. Pitha-Rowe I, Liby K, Royce D, and Sporn M. Synthetic
triterpenoids attenuate cytotoxic retinal injury: cross-talk
between Nrf2 and PI3K/AKT signaling through inhibition
of the lipid phosphatase PTEN. Invest Ophthalmol Vis Sci
50: 5339–5347, 2009.
121. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH;
Vitamins in Pre-eclampsia (VIP) Trial Consortium. Vita-
min C and vitamin E in pregnant women at risk for pre-
eclampsia (VIP trial): randomised placebo-controlled trial.
Lancet 367: 1145–1154, 2006.
122. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD,
and Cuadrado A. SCF/{beta}-TrCP promotes glycogen
synthase kinase 3-dependent degradation of the Nrf2
ANTIOXIDANTS IN TRANSLATIONAL MEDICINE 1141
transcription factor in a Keap1-independent manner. Mol
Cell Biol 31: 1121–1133, 2011.
123. Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG,
Cotte A, Jaworski T, Tobon-Velasco JC, Devijver H,
Garcia-Mayoral MF, Van Leuven F, Hayes JD, Bertho G,
and Cuadrado A. Structural and functional characterization
of Nrf2 degradation by the glycogen synthase kinase 3/
beta-TrCP axis. Mol Cell Biol 32: 3486–3499, 2012.
124. Ray PD, Huang BW, and Tsuji Y. Reactive oxygen spe-
cies (ROS) homeostasis and redox regulation in cellular
signaling. Cell Signal 24: 981–990, 2012.
125. Ristow M, Zarse K, Oberbach A, Kloting N, Birringer M,
Kiehntopf M, Stumvoll M, Kahn CR, and Bluher M.
Antioxidants prevent health-promoting effects of physical
exercise in humans. Proc Natl Acad Sci U S A 106: 8665–
8670, 2009.
126. Rojo AI, Medina-Campos ON, Rada P, Zuniga-Toala A,
Lopez-Gazcon A, Espada S, Pedraza-Chaverri J, and
Cuadrado A. Signaling pathways activated by the phyto-
chemical nordihydroguaiaretic acid contribute to a Keap1-
independent regulation of Nrf2 stability: role of glycogen
synthase kinase-3. Free Radic Biol Med 52: 473–487, 2012.
127. Rojo AI, Rada P, Mendiola M, Ortega-Molina A, Wojdyla
K, Rogowska-Wrzesinska A, Hardisson D, Serrano M, and
Cuadrado A. The PTEN/NRF2 axis promotes human car-
cinogenesis. Antioxid Redox Signal 21: 2498–2514, 2014.
128. Salvemini D and Riley DP. Nonpeptidyl mimetics of su-
peroxide dismutase in clinical therapies for diseases. Cell
Mol Life Sci 57: 1489–1492, 2000.
129. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P,
and Bergo MO. Antioxidants accelerate lung cancer pro-
gression in mice. Sci Transl Med 6: 221ra15, 2014.
130. Schencking M, Vollbracht C, Weiss G, Lebert J, Biller A,
Goyvaerts B, and Kraft K. Intravenous Vitamin C in the
treatment of shingles: results of a multicenter prospective
cohort study. Med Sci Monit 18: CR215–CR224, 2012.
131. Seidel P and Roth M. Anti-inflammatory dimethylfuma-
rate: a potential new therapy for asthma? Mediators In-
flamm 2013: 875403, 2013.
132. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C,
MacFadyen J, Bubes V, Manson JE, Glynn RJ, and Ga-
ziano JM. Vitamins E and C in the prevention of cardio-
vascular disease in men: the Physicians’ Health Study II
randomized controlled trial. JAMA 300: 2123–2133, 2008.
133. Shekelle PG, Morton SC, Jungvig LK, Udani J, Spar M, Tu
W, M JS, Coulter I, Newberry SJ, and Hardy M. Effect of
supplemental vitamin E for the prevention and treatment of
cardiovascular disease. J Gen InternMed 19: 380–389, 2004.
134. Shen Y, Cai W, Lei S, and Zhang Z. Effect of high/low
dose N-acetylcysteine on chronic obstructive pulmonary
disease: a systematic review and meta-analysis. COPD 11:
351–358, 2014.
135. Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis
SM, Diener HC, Ashwood T, Wasiewski WW, Emeribe U;
SAINT II Trial Investigators. NXY-059 for the treatment of
acute ischemic stroke. N Engl J Med 357: 562–571, 2007.
136. Sies H. Oxidative stress: a concept in redox biology and
medicine. Redox Biol 4: 180–183, 2015.
137. Sleight P. The HOPE Study (Heart Outcomes Prevention
Evaluation). J Renin Angiotensin Aldosterone Syst 1: 18–
20, 2000.
138. Smith RA, Hartley RC, and Murphy MP. Mitochondria-
targeted small molecule therapeutics and probes. Antioxid
Redox Signal 15: 3021–3038, 2011.
139. Spanier G, Xu H, Xia N, Tobias S, Deng S, Wojnowski L,
Forstermann U, and Li H. Resveratrol reduces endothelial
oxidative stress by modulating the gene expression of
superoxide dismutase 1 (SOD1), glutathione peroxidase 1
(GPx1) and NADPH oxidase subunit (Nox4). J Physiol
Pharmacol 60 Suppl 4: 111–116, 2009.
140. Stacey MM, Vissers MC, and Winterbourn CC. Oxidation
of 2-cys peroxiredoxins in human endothelial cells by
hydrogen peroxide, hypochlorous acid, and chloramines.
Antioxid Redox Signal 17: 411–421, 2012.
141. Stocker R. The ambivalence of vitamin E in atherogene-
sis. Trends Biochem Sci 24: 219–223, 1999.
142. Tanaka H, Matsuda T, Miyagantani Y, Yukioka T, Mat-
suda H, and Shimazaki S. Reduction of resuscitation fluid
volumes in severely burned patients using ascorbic acid
administration: a randomized, prospective study. Arch
Surg 135: 326–331, 2000.
143. Thompson JS, Chu Y, Glass J, Tapp AA, and Brown SA.
The manganese superoxide dismutase mimetic, M40403,
protects adult mice from lethal total body irradiation. Free
Radic Res 44: 529–540, 2010.
144. Timmers S, Konings E, Bilet L, Houtkooper RH, van de
Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu
D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I,
Schrauwen-Hinderling VB, Blaak EE, Auwerx J, and
Schrauwen P. Calorie restriction-like effects of 30 days of
resveratrol supplementation on energy metabolism and
metabolic profile in obese humans. Cell Metab 14: 612–
622, 2011.
145. Tong KI, Katoh Y, Kusunoki H, Itoh K, Tanaka T, and
Yamamoto M. Keap1 recruits Neh2 through binding to
ETGE and DLG motifs: characterization of the two-site
molecular recognition model. Mol Cell Biol 26: 2887–
2900, 2006.
146. Tsianakas A, Herzog S, Landmann A, Patsinakidis N, Per-
usquia Ortiz AM, Bonsmann G, Luger TA, and Kuhn A.
Successful treatment of discoid lupus erythematosus with
fumaric acid esters. J AmAcadDermatol 71: e15–e17, 2014.
147. Vanden Berghe T, Linkermann A, Jouan-Lanhouet S,
Walczak H, and Vandenabeele P. Regulated necrosis: the
expanding network of non-apoptotic cell death pathways.
Nat Rev Mol Cell Biol 15: 135–147, 2014.
148. Venditti P, Napolitano G, Barone D, and Di Meo S. Effect
of training and vitamin E administration on rat liver oxi-
dative metabolism. Free Radic Res 48: 322–332, 2014.
149. Venturelli S, Sinnberg TW, Berger A, Noor S, Levesque
MP, Bocker A, Niessner H, Lauer UM, Bitzer M, Garbe
C, and Busch C. Epigenetic impacts of ascorbate on hu-
man metastatic melanoma cells. Front Oncol 4: 227, 2014.
150. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, and Topol
EJ. Use of antioxidant vitamins for the prevention of
cardiovascular disease: meta-analysis of randomised tri-
als. Lancet 361: 2017–2023, 2003.
151. Wang YY, Yang YX, Zhe H, He ZX, and Zhou SF.
Bardoxolone methyl (CDDO-Me) as a therapeutic agent:
an update on its pharmacokinetic and pharmacodynamic
properties. Drug Des Devel Ther 8: 2075–2088, 2014.
152. Welsh JL, Wagner BA, van’t Erve TJ, Zehr PS, Berg DJ,
Halfdanarson TR, Yee NS, Bodeker KL, Du J, Roberts LJ,
2nd, Drisko J, Levine M, Buettner GR, and Cullen JJ.
Pharmacological ascorbate with gemcitabine for the con-
trol of metastatic and node-positive pancreatic cancer
(PACMAN): results from a phase I clinical trial. Cancer
Chemother Pharmacol 71: 765–775, 2013.
1142 SCHMIDT ET AL.
153. Wendel A, Fausel M, Safayhi H, Tiegs G, and Otter R. A
novel biologically active seleno-organic compound—II.
Activity of PZ 51 in relation to glutathione peroxidase.
Biochem Pharmacol 33: 3241–3245, 1984.
154. Wind S, Beuerlein K, Armitage ME, Taye A, Kumar AH,
Janowitz D, Neff C, Shah AM, Wingler K, and Schmidt
HH. Oxidative stress and endothelial dysfunction in aortas
of aged spontaneously hypertensive rats by NOX1/2 is
reversed by NADPH oxidase inhibition. Hypertension 56:
490–497, 2010.
155. Xia N, Daiber A, Habermeier A, Closs EI, Thum T,
Spanier G, Lu Q, Oelze M, Torzewski M, Lackner KJ,
Munzel T, Forstermann U, and Li H. Resveratrol reverses
endothelial nitric-oxide synthase uncoupling in apolipo-
protein E knockout mice. J Pharmacol Exp Ther 335:
149–154, 2010.
156. Yeom CH, Lee G, Park JH, Yu J, Park S, Yi SY, Lee HR,
Hong YS, Yang J, and Lee S. High dose concentration
administration of ascorbic acid inhibits tumor growth in
BALB/C mice implanted with sarcoma 180 cancer cells via
the restriction of angiogenesis. J Transl Med 7: 70, 2009.
157. Yusuf S, Dagenais G, Pogue J, Bosch J, and Sleight P. Vi-
tamin E supplementation and cardiovascular events in high-
risk patients. The Heart Outcomes Prevention Evaluation
Study Investigators. N Engl J Med 342: 154–160, 2000.
158. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, and Da-
genais G. Effects of an angiotensin-converting-enzyme
inhibitor, ramipril, on cardiovascular events in high-risk
patients. The Heart Outcomes Prevention Evaluation
Study Investigators. N Engl J Med 342: 145–153, 2000.
Address correspondence to:
Dr. Andreas Daiber
Labor fu¨r Molekulare Kardiologie
II. Medizinische Klinik und Poliklinik
Universita¨tsmedizin der Johannes Gutenberg-Universita¨t
Langenbeckstr.1
55131 Mainz
Germany
E-mail: daiber@uni-mainz.de
Dr. Antonio Cuadrado
Instituto de Investigaciones Biome´dicas
‘‘Alberto Sols’’ UAM-CSIC
C/Arturo Duperier 4
Madrid 28029
Spain
E-mail: antonio.cuadrado@uam.es
Date of first submission to ARS Central, May 23, 2015; date
of final revised submission, June 26, 2015; date of accep-
tance, July 3, 2015.
Abbreviations Used
AKT¼ protein kinase B
ARE¼ antioxidant response element
BH4¼ tetrahydrobiopterin
BO-653¼ 2,3-dihydro-5-hydroxy-2,2-dipentyl-
4,6-di-tert-butylbenzofuran
CDDO; CDDO-Im¼ 2-cyano-3,12-dioxooleana-1,9-
dien-28-oic acid-imidazolide
CVD¼ cardiovascular disease
DMF¼ dimethyl fumarate
eNOS¼ endothelial nitric oxide synthase
ERK¼ extracellular signal-regulated kinases
gp91phox¼ 91kDa membranous subunit of the
phagocyte NADPH oxidase (Nox2)
GSH¼ glutathione
H2O2¼ hydrogen peroxide
JNK¼ c-Jun N-terminal kinases
KEAP1¼ kelch-like ECH-associated protein 1
MAPK¼mitogen-activated protein kinase
miRNA¼microRNA, a small noncoding RNA
molecule
mitoTEMPO¼ (2-(2,2,6,6-Tetramethylpiperidin-1-
oxyl-4-ylamino)-2-
oxoethyl)triphenylphosphonium
chloride monohydrate
MMF¼monomethyl fumarate
MS¼multiple sclerosis
NAC¼N-acetylcysteine
NADPH¼ nicotinamide adenine dinucleotide
phosphate
NO¼ nitric oxide
NOS¼ nitric oxide synthase
NOX¼ nicotinamide adenine dinucleotide
phosphate oxidases
(1, 2, 4 isoforms)
NRF2¼ nuclear factor (erythroid-derived 2)-
like 2
NXY-059¼ disufenton sodium, a synthetic
antioxidant
O2
- ¼ superoxide anion
p38¼ p38 mitogen-activated protein kinases
PGC1a¼ peroxisome proliferator-activated
receptor gamma coactivator 1a
PTEN¼ phosphatase and tensin homolog
ROS¼ reactive oxygen species
SOD¼ superoxide dismutase
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